Label: Information for the Patient
Rubicrono 27 mg prolonged-release tablets EFG
methylphenidate, hydrochloride
Read this label carefully before you or your child start taking this medicine, because it contains important information for you.
1. What is Rubicrono and what it is used for
2. What you need to know before you or your child start taking Rubicrono
3. How to take Rubicrono
4. Possible side effects
5. Storage of Rubicrono
6. Contents of the pack and additional information
What it is used for
Rubicronois used to treat “attention deficit hyperactivity disorder” (ADHD).
Rubicronois not indicated for the treatment of ADHD in children under 6 years.
How it works
Rubicronoimproves the activity of certain parts of the brain that have low activity. The medication may help improve attention (level of attention), concentration, and reduce impulsive behavior.
The medication is administered as part of a comprehensive treatment program, which usually includes:
Only prescribe by doctors who have experience in behavioral problems in children, adolescents, or adults.If you are an adult and have not received treatment before, the specialist will perform tests to confirm that you have had ADHD since childhood. Although ADHD does not have a cure, it can be controlled using comprehensive treatment programs.
About ADHD
Children and adolescents with ADHD have difficulty:
It is not their fault that they cannot do these things.
Many children and adolescents struggle to do them. However, ADHD can cause problems in daily life. Children and adolescents with ADHD may have difficulty learning and doing homework. They have difficulty behaving well at home, school, and other places.
Adults with ADHD often have difficulty concentrating. They often feel restless, impatient, and distracted. They may have difficulty organizing their personal and work life.
Not all patients with ADHD need medication treatment.
ADHD does not affect intelligence.
Do not takeRubicronoif you or your child:
Do not take methylphenidate if you or your child experience any of the above. If you are unsure, inform your doctor or pharmacist before you or your child take methylphenidate. This is because methylphenidate may worsen these problems.
Warnings and precautions
Consult your doctor before starting to take Rubicrono if you or your child:
Other mental health problems include:
Inform your doctor or pharmacist if you or your child experience any of the above before starting treatment. This is because methylphenidate may worsen these problems. Your doctor will want to monitor how the medication affects you or your child.
During treatment, male patients may experience, unexpectedly, prolonged erections. Erections can be painful and occur at any time. It is essential to contact your doctor immediately if the erection lasts more than 2 hours, especially if it is painful.
Checks your doctor will make before you or your child start treatment with Rubicrono
To decide if methylphenidate is the right medication for you or your child, your doctor will discuss with you:
It is essential to provide all the information you can. This will help your doctor decide if methylphenidate is the right medication for you or your child. Your doctor may decide that you or your child need other medical tests before starting this medication.Your doctor may refer you to a cardiologist if you are an adult starting to take Rubicrono.
Other medications and Rubicrono
Inform your doctor if you are taking, have taken recently, or may need to take any other medication.
Do not take methylphenidate if you or your child:
Taking methylphenidate with these types of medications may produce a potentially fatal increase in "serotonin" in the brain (serotonin syndrome), which can cause confusion or restlessness, sweating, chills, muscle spasms, or rapid heartbeats. If you or your child experience these adverse effects, see your doctor immediately.
If you or your child are taking other medications, methylphenidate may affect the mechanism of action of these medications or cause adverse effects. If you or your child are taking any of the following medications, consult your doctor or pharmacist before taking methylphenidate:
If you have any doubts about whether any of the medications you or your child are taking are included in the above list, consult your doctor or pharmacist for advice before taking methylphenidate.
Before surgery
Inform your doctor if you or your child are undergoing surgery. Do not take methylphenidate on the day of surgery with certain types of anesthetics, as it may cause a sudden increase in blood pressure during the procedure.
Drug analysis
This medication may produce a positive result in drug tests, even in tests used in sports.
Taking Rubicrono with alcohol
Do not drink alcohol while taking this medication. Alcohol may worsen the adverse effects of this medication. Remember that some foods and medications contain alcohol.
Pregnancy, lactation, and contraception
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor before using this medication.
The available data do not suggest an increased risk of congenital anomalies, although a small increased risk of cardiac malformations cannot be ruled out during the first three months of pregnancy. Your doctor will provide more information about this risk. Consult your doctor or pharmacist before using methylphenidate if you or your daughter:
Driving and operating machinery
You may experience dizziness, drowsiness, and visual disturbances during treatment with methylphenidate. If these side effects occur, it may be hazardous to perform certain activities (such as driving, operating machinery, riding a bike, or climbing trees) until you are sure you or your child are not affected.
Rubicrono contains lactose
This medication contains lactose (a type of sugar). If your doctor has told you or your child that you have an intolerance to certain sugars, consult with them before taking this medication.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The tablet should be swallowed whole and not chewed, broken, or crushed. The tablet can be taken with or without food.
Use in children aged 6 and above
The recommended initial dose of Rubicrono is 18 mg once a day for children who are not currently taking methylphenidate, or for children who are switching from another stimulant to methylphenidate.
The maximum daily dose is 54 mg.
Use in adults
If you or your child do not improve after 1 month of treatment
Inform your doctor. Your doctor may decide if you need a different treatment.
What your doctor will do when you or your child are on treatment
Your doctor will perform some tests
Long-term treatment
Rubicrono does not need to be taken indefinitely. If you or your child take Rubicrono for more than a year, your doctor should interrupt treatment for a short period, such as during school holidays. This allows you to demonstrate if you still need the medication.
Abuse of Rubicrono
If Rubicrono is not used properly, it may cause abnormal behavior. This can also mean that you or your child start to depend on the medication. Inform your doctor if you or your child have abused or been dependent on alcohol, prescription medications, or drugs.
This medication is only for you or your child. Do not give this medication to anyone else, even if they have similar symptoms.
If you or your child take more Rubicrono than they should
If you or your child take too many tablets, consult your doctor immediately or go to the nearest hospital emergency department and tell them how many tablets were taken. Medical treatment may be necessary.
You can also contact the Toxicology Information Service, Phone 91 5620420, indicating the medication and the amount taken. It is recommended to bring the packaging and the medication leaflet to the healthcare professional.
The signs of overdose may include: nausea, agitation, tremors, increased uncontrolled movements, muscle contractions, seizures (which may be followed by coma), feeling extremely happy, confusion, seeing, feeling, or hearing things that are not real (hallucinations), sweating, flushing, headache, high fever, changes in heart rate (slow, fast, or irregular), high blood pressure, dilated pupils, dryness of the nose and mouth, muscle swelling, weak and sensitive muscles, muscle pain, dark urine.
If you or your child forget to take Rubicrono
Do not take a double dose to compensate for the missed dose. If you or your child forget a dose, wait to take the next dose at the scheduled time.
If you or your child stop taking Rubicrono
If you or your child stop taking this medication suddenly, the symptoms of ADHD or unwanted effects such as depression may reappear. Your doctor may want to gradually reduce the amount of medication taken each day before stopping it completely. Consult your doctor before stopping treatment with Rubicrono.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Some side effects can be serious. If you or your child have any of the side effects listed below, seek immediate medical attention:
Frequent (can affect up to 1 in 10 people)
Less frequent (can affect up to 1 in 100 people)
Rare (can affect up to 1 in 1,000 people)
Very rare (can affect up to 1 in 10,000 people)
Unknown frequency (cannot be estimated from available data)
If you or your child have any of the side effects listed above, seek immediate medical attention.
The following side effects are listed below, and if they become serious, please inform your doctor or pharmacist:
Very frequent (can affect more than 1 in 10 people)
Frequent (can affect up to 1 in 10 people)
Less frequent (can affect up to 1 in 100 people)
Rare (can affect up to 1 in 1,000 people)
Very rare (can affect up to 1 in 10,000 people)
Unknown frequency (cannot be estimated from available data)
Effects on growth
When used for more than a year, methylphenidate may reduce growth in some children. This affects less than 1 in 10 children.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not usethis medicationafter the expiration date that appears on the packaging after “CAD”. The expiration date is the last day of the month indicated.
This medication does not require special conditions for conservation.
Expiration after opening the packaging:
27 mg tablets: 6 months
Medicines should not bethrown down the drains or in the trash.Deposit the packaging and the medicines that you do not need at the SIGREpoint of the pharmacy. In case of doubtask your pharmacist how to dispose of the packaging and the medicines that you do not need. By doing so, you will help protect the environment..
The active ingredient ismethylphenidate hydrochloride
The other components are: lactose monohydrate, hypromellose, anhydrous colloidal silica, magnesium stearate, fumaric acid, copolymer of methacrylic acid-methyl methacrylate (1:1), copolymer of methacrylic acid-methyl methacrylate (1:2), triethyl citrate, talc
Coating:
27 mg: partially hydrolyzed polyvinyl alcohol, macrogol (3350), talc, titanium dioxide (E171), yellow iron oxide (E172), indigo carmine lake (E132), black iron oxide (E172).
Printing ink:
Shellac, black iron oxide (E172), and propylene glycol.
Appearance of the product and contents of the package
27 milligram tablet: biconvex tablet, capsule-shaped, gray in color, 6.7 mm x 12 mm, with "2393" printed in black on one face
The medicine is presented in child-resistant bottles with silica gel desiccant inserted in the cap, containing 28, 29, 30, or 100 prolonged-release tablets.
Only some package sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder
Laboratorios Rubió, S.A.
Industria 29 – Pol. Ind. Comte de Sert
08755 Castellbisbal
Barcelona, Spain
Responsible manufacturer
Balkanpharma Dupnitsa AD
3 Samokovsko Shosse Str
Dupnitsa 2600, Bulgaria
This medicine is authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) with the following names:
GermanyKinecteen 27mg Retardtabletten
NetherlandsKinecteen tablets with prolonged release
SpainRubicrono 27 mg prolonged-release tablets EFG
United Kingdom (Northern Ireland)Xaggitin XL 27mg Prolonged-release Tablets
Last review date of this leaflet: November 2023
For detailed and updated information on this medicine, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.